When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy?

Annals of Thoracic Surgery

Volumn 84, Issue 4, 2007, Pages 1092-1097

  Cerfolio, Robert James ^a   Bryant, Ayesha S ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34548693685     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.05.050     Document Type: Article

References (23)

1. Bulzebruck H., Bopp R., Drings P., et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70 (1992) 1102-1110
2. Cerfolio R.J., Ojha B., Bryant A.S., Bass C.S., Bartalucci A.A., and Mountz J.M. The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 76 (2003) 861-866
3. Lardinois D., Weder W., Hany T.F., et al. Stating of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
4. Aquino S.L., Asmuth J.C., Alpert N.M., Halpern E.F., and Fischman A.J. Improved radiologic staging of lung cancer with 2-[18]-flouro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration. J Comput Assist Tomogr 27 (2003) 479-484
5. Cerfolio R.J., Bryant A.S., Ojha B., and Eloubeidi M. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 80 (2005) 1207-1214
6. Reed C.E., Harpole D.H., Posther K.E., et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1943-1951
7. Cerfolio R.J. Positron emission tomography scanning with 2-fluoro-2-deoxyglucose as a predictor of response for non-small cell cancer. J Thorac Cardiovasc Surg 125 (2003) 938-944
8. Mawlawi O., Pan T., and Macapinla H.A. PET/CT Imaging techniques, considerations and artifacts. J Thorac Imaging 21 (2006) 99-110
9. Hautzel H., and Muller-Gartner H. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 38 (1997) 1384-1386
10. Nabi H.A., and Zubeldia J.M. Clinical applications of F18-FDG in oncology. J Nucl Med Technol 30 (2002) 3-9
11. Cerfolio R.J., Bryant A.S., Winokur T.S., Ohja B., and Bartolucci A.A. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78 (2004) 1903-1909
12. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
13. Cerfolio R.J., Bryant A.S., and Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 131 (2006) 1229-1235
14. Beck J. Likelihood ratios: another enhancement of sensitivity and specificity. Arch Pathol Lab Med 110 (1986) 685-686
15. Sonett J.R., Krasna M.J., Suntharalingam M., et al. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation. Ann Thorac Surg 68 (1999) 316-320
16. Cerfolio R.J., Bryant A.S., Spencer S.A., and Bartolucci A.A. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 80 (2005) 1224-1230
17. Cerfolio R.J., Bryant A.S., and Yamamura M. Intercostal muscle flap to buttress the bronchus at risk and the thoracic esophageal-gastric anastomosis. Ann Thorac Surg 80 (2005) 1017-1020
18. Pisters K.M., Kris M.G., Gralla R.J., Zaman M.B., Heelan R.T., and Martini N. Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: implications for the design of future non-small cell lung cancer combined modality trials. J Clin Oncol 11 (1993) 1757-1762
19. Gillham C.M., Lucey J.A., Keogan M., et al. (18) FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 95 (2006) 1174-1179
20. Higashi K., Clavo A.C., and Wahl R.L. In vitro assessment of 2-flouro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell like to radiotherapy. J Nucl Med 34 (1993) 773-779
21. Schneeweiss F.A., Sharan F.N., Hautzel H., Rub T.H., and Muller-Gartner H.W. Effect of ionizing radiation on conversion factor between deoxyglucose and glucose (lumped constant) in human glioblastoma cells in vitro. J Nucl Med 36 (1995) 202
22. Bryant A.S., Cerfolio R.J., Klemm K.M., and Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 82 (2006) 417-422
23. Weber W.A., Ziegler S.I., Thodtmann R., Hanauske A., and Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG-PET. J Nucl Med 40 (1999) 1771-1777